Gelonghui, May 17 | Haofan Biology (301393.SZ) said on the investor interactive platform that the company has no layout in the field of synthetic biology and has no cooperation in AI pharmaceuticals. The company's main products are polypeptide synthesis reagents, which can be widely used in the development and production of small-molecule chemical drugs and polypeptide drugs containing amide bonds, and have good commercial prospects.
昊帆生物(301393.SZ)：在合成生物领域尚无布局，在AI制药方面暂无合作
Haofan Biology (301393.SZ): No layout in the field of synthetic biology, no cooperation in AI pharmaceuticals
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.